NeuropacevsUnitedHealth

NPCE and UNH stock compared: price, dividend, valuation and results, from SEC filings.

NPCE

Neuropace, Inc.

$8.22

Value $277M

+0.24%
NPCE's page

UNH

UnitedHealth Group Incorporated

$349.91

Value $318B

-10.21%
UNH's page

Neuropace (NPCE) has a market value of $277M and UnitedHealth (UNH) $318B. Over the last year, with dividends, NPCE moved -36.5% and UNH +12.1%. Dividend yield: NPCE none, UNH 2.59%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    NPCE$277M

    UNH$318B

    UNH is 1,148 times NPCE

  • Revenue, 12 months

    NPCE$103M

    UNH$450B

    UNH is 4,382 times NPCE

  • Net income, 12 months

    NPCE-$19M

    UNH$15.9B

  • Operating margin

    NPCE-11.5%

    UNH5.3%

    16.8 points apart

  • ROIC

    NPCE-12.6%

    UNH11.3%

    23.9 points apart

  • P/E

    NPCE–

    UNH20.0

  • Dividend yield

    NPCE0.0%

    UNH2.6%

    2.6 points apart

  • 5-year return

    NPCE-30.3%

    UNH-14.7%

    15.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

NPCE-30.4%

UNH-14.7%

5010015020222023202420252026
Returns by period
PeriodNPCEWith dividendsUNHWith dividends
1 year since November 17, 2025-36.5%Price -36.5%+12.1%Price +9.2%
3 years since November 17, 2023-5.0%-1.7% a yearPrice -5.0%-30.5%-11.4% a yearPrice -34.8%
5 years since November 17, 2021-30.3%-7.0% a yearPrice -30.3%-14.7%-3.1% a yearPrice -22.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

NPCENeuropaceUNHUnitedHealth

Valuation

NPCEUNH
Valuation
Price$8.22$349.91
Market value$277M$318B
Enterprise value (EV)–$363B
P/E–20.0
P/E, 5-year median–25.0
P/B24.13.1
EV/EBIT–15.2
Free cash flow yield–7.2%

Results and growth

NPCEUNH
Results and growth
Revenue, 12 months$103M$450B
Net income, 12 months-$19M$15.9B
Free cash flow, 12 months-$12M$22.8B
Earnings per share, 12 months-$0.56$17.52
Revenue growth, year on year25.1%11.8%
Revenue growth a year, past+19.4%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

NPCEUNH
Margins and returns on capital
Gross margin78.9%88.3%
Operating margin-11.5%5.3%
Net margin-18.4%3.5%
ROIC-12.6%11.3%
ROE-125.5%15.5%

Balance sheet

NPCEUNH
Balance sheet
Cash$49M$28.5B
Total debt–$74.3B
Net debt / EBITDA–1.6
Interest cover-1.9×6.2×

Dividends and buybacks

NPCEUNH
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield17.9%1.8%
Shareholder yield17.9%4.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: NPCE or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Neuropace or UnitedHealth?

By market value, UnitedHealth ($318B) is about 1,147.7 times Neuropace ($277M), at today's prices.

How did NPCE and UNH stock do over the last 5 years?

Since November 17, 2021, NPCE's price moved -30.3% and UNH's -22.1%. With dividends: NPCE -30.3% (-7.0% a year), UNH -14.7% (-3.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, NPCE or UNH?

The dividend yield at today's price is none for Neuropace and 2.59% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Neuropace or UnitedHealth?

Over the last twelve months, the net margin was -18.4% for Neuropace and 3.5% for UnitedHealth, and the operating margin -11.5% and 5.3%. Revenue was $103M and $450B.

Which is the better investment, Neuropace or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.